Topics
Breast Cancer
Gastrointestinal Cancer
- Colorectal Cancer
- Hepatocellular Cancer
- Pancreatic Cancer
Genitourinary Cancer
- Prostate Cancer
- Renal Cell Carcinoma
Glioblastoma
Gynecologic Cancer
- Ovarian Cancer
Head & Neck Cancer
Hematologic Malignancies
- Leukemias
- Lymphomas
- Multiple Myeloma
Lung cancer
Skin Cancer
Translational Research
Supportive Care
Conference Coverage
2013 Gastrointestinal Cancers Symposium
2012 American Society of Hematology Annual Meeting
2012 San Antonio Breast Cancer Symposium
2012 American Society of Clinical Oncology Annual Meeting
2012 Genitourinary Cancers Symposium
More...
Education
ClinicalQuiz™: Metastatic Breast Cancer Edition
Research Focus: Agents Targeting Novel B-Cell Pathways in Hematologic Malignancies
ClinicalQuiz™: Non-Small-Cell Lung Cancer, Educational Material
2013 GI Symposium
Management of Newly Diagnosed Metastatic Melanoma With a Wild-Type BRAF Genotype
More...
ClinicalThought
What Is the Best Approach in MDS When Hypomethylating Agents Fail?
Bladder Cancer: Are Changes in Chemotherapy Warranted?
How I Manage Patients With Relapsed/Refractory T-Cell Lymphomas
How Do We Improve Current Therapy for MCL? Here Are 4 Promising Possibilities
HER2-Positive Metastatic Breast Cancer: How Do You Present the Choices to Your Patient?
More...
Decision Support
inPractice
Decision Support Tools
Guidelines
CCO Live Events
Slidesets & Resources
Audio
Cases
CCO Store
Expert Viewpoints
NCCN Cases
Oncology Nursing
Slidesets
Video
Save Bookmark
Email to a Colleague
CCO Home
/
Oncology
/
Treatment Updates
/ HR-Positive, HER2-Negative Breast Cancer
Clinical Focus: Current Approaches to the Treatment of HR-Positive, HER2-Negative Metastatic Breast Cancer
Table of Contents
Module
•
HR+, HER2- Breast Cancer
Slideset
•
HR+, HER2- Breast Cancer
Program Overview
Clinical Focus: Current Approaches to the Treatment of HR-Positive, HER2-Negative Metastatic Breast Cancer
In this review of HR-positive, HER2-negative metastatic breast cancer, Denise Yardley, MD, discusses and presents interactive case examples of the role of hormonal therapy in this disease and the prospects for further improvement of outcomes through the incorporation of novel agents.
Latest Content
2 of 2 Shown
Clinical Focus: Current Approaches to the Treatment of Hormone Receptor–Positive, HER2-Negative Metastatic Breast Cancer
Denise A. Yardley, MD, explores current treatment options for hormone receptor–positive, HER2-negative metastatic breast cancer.
Source:
Clinical Focus: Current Approaches to the Treatment of HR-Positive, HER2-Negative Metastatic Breast Cancer
Date Posted:
1/15/2013
Clinical Focus: Current Approaches to the Treatment of Hormone Receptor–Positive, HER2-Negative Metastatic Breast Cancer
Denise A. Yardley, MD, explores current treatment options for hormone receptor–positive, HER2-negative metastatic breast cancer.
Source:
Clinical Focus: Current Approaches to the Treatment of HR-Positive, HER2-Negative Metastatic Breast Cancer
Faculty:
Denise A. Yardley MD
Released:
1/15/2013
2 of 2 Shown
Show 0 More
Loading...
Jointly sponsored by Postgraduate Institute for Medicine and Clinical Care Options, LLC
Contact Info
Educational grant provided by:
Educational grants support only the CME-certified components of this program.